Greenland Mines Secures Canadian Patent for Klotho Gene Therapy
Greenland Mines Ltd announced that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398, titled "SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND MEMORY." This patent protects the use of a human gene therapy utilizing a nucleic acid gene sequence encoding the secreted Klotho (s-KL) protein, with 42 claims covering its utility in treating various neurodegenerative diseases. The company now holds patents for its product candidate KLTO-101 in all major markets, and KLTO-101 is set to begin process development and manufacturing in August 2026. Additionally, KLTO-202 for ALS and other neuromuscular disorders has advanced to the GMP manufacturing stage.
Key Highlights
- Greenland Mines secured Canadian Patent No. CA3,005,398 for Klotho gene therapy.
- Patent covers 'SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND MEMORY'.
- Protects use of human gene therapy using nucleic acid gene sequence for secreted Klotho (s-KL).
- Includes 42 granted claims for s-KL utility in treating neurodegenerative diseases.
- KLTO-101, covered by the patent, will begin process development and manufacturing in August 2026.
- KLTO-202 for ALS and neuromuscular disorders advanced to GMP manufacturing stage.
- Company now holds patents for KLTO-101 in major markets including US, China, Europe, and Canada.
Price Impact
More from GRML